Brain Tumor
RSSArticles
-
Decisional Capacity Is Most Common Issue in Neuro-Oncologic Ethical Consults
For a terminal condition, goals of care need to be identified so they can be honored. If discussions do not happen early, when the patient likely is at his or her peak functional status, it leaves caregivers, families, and physicians with little guidance.
-
Viral Therapy for Glioblastoma
In a Phase I/II trial, convection-enhanced delivery of an engineered poliovirus yielded similar median overall survival compared to historical controls. However, a small subgroup of treated patients had extended survival past two years.
-
How Helpful Is Bevacizumab in Recurrent Glioblastoma?
In a randomized Phase III trial, the addition of bevacizumab to lomustine did not improve overall survival in patients with recurrent glioblastoma compared to lomustine alone.
-
Pitfalls in the Treatment of Seizures Associated With Brain Tumors
In this multicenter, observational study, the authors assessed the prevalence of neuropsychiatric side effects from medications in subjects with tumor-related epilepsy. Levetiracetam was found to have the highest prevalence of such side effects.
-
Rituximab May Be Effective for Refractory Myasthenia Gravis
In a restrospective review, rituximab appeared beneficial for patients with medication-resistant myasthenia gravis. -
When Is it Best to Evaluate the Results of a CSF Tap Test?
The tap test has variable results as a tool to assess patients with a presumed diagnosis of normal pressure hydrocephalus. -
Surgical Treatment of Brain Metastases
Surgical removal of brain metastases remains an important part of palliative therapy for metastatic cancer. -
Women with Migraine: Options for Decreasing Disability
Menstrually related migraine is difficult to treat and options are limited. Hormonal manipulation is controversial and unproven. -
Clinical Briefs in Primary Care Supplement
-
Teriflunomide: A New Oral Agent for the Treatment of Multiple Sclerosis
Teriflunomide, an orally administered inhibitor of dihydro-orotate dehydrogenase, was found to be superior to placebo in reducing relapses in a 2-year, Phase 3 clinical trial in patients with multiple sclerosis.